Organised by Shanghai JiaoTong University
Chair(s)
MD Yujin Guo, Jining First People’s Hospital, China
Introduction:
Anticoagulant therapy is essential in managing thromboembolic disorders like venous thromboembolism (VTE) and atrial fibrillation (AF). Advances such as direct oral anticoagulants (DOACs) have transformed treatment, yet challenges remain, including balancing efficacy and safety, managing drug interactions, and improving adherence. This session aims to bridge practice and research by showcasing innovations, addressing clinical challenges, and exploring personalized strategies to enhance outcomes. Through expert presentations and discussions, attendees will gain actionable insights to optimize anticoagulant use, improve patient safety, and advance care in this critical area.
Programme:
| 13:00 – 13:10 | Chair introduction & Welcome speech |
| MD Yujin Guo, Jining First People’s Hospital, China | |
| Prof Virginia Olmos, Vice President, FIP, Uruguay | |
| 13:10 – 13:30 | Optimizing Anticoagulant Use: Current Practices and future Considerations from Pharmacist's Perspective |
| Dr Houwen Lin, Shanghai JiaoTong University School of Medicine, China | |
| 13:30 – 13:50 | Epidemiological Characteristics of VTE and Current Anticoagulation Practices in Postoperative Colorectal Cancer Patients in China |
| Zhichun Gu, Shanghai JiaoTong University School of Medicine, China | |
| 13:50 – 14:00 | Q&A & Closing |
Learning objectives:
1. To understand current best practices and safety considerations in the clinical use of anticoagulant therapies for diverse patient populations.
2. To explore recent advancements and novel mechanisms of action in anticoagulant development and their implications for clinical practice.
3. To foster the integration of research findings into clinical decision-making, enhancing personalized approaches to anticoagulant therapy for improved patient outcomes.
Take home messages:
1. Anticoagulant therapy remains a cornerstone in preventing and managing thromboembolic disorders, but personalized approaches are critical for optimizing safety and efficacy.
2. Recent advancements in anticoagulants, including novel drug classes, offer new opportunities but require careful evaluation and integration into practice.
3. Collaborative efforts between researchers, clinicians, and pharmacists are essential to bridge gaps in knowledge, improve adherence, and translate innovations into improved patient care.
